

Special Issue

Non-specific Protections in Response to Vaccination and Other Stimulations of the Immune System

Message from the Guest Editors

In the era of coronavirus disease 2019 (COVID-19) and antimicrobial resistance, vaccination is more than ever the best way to protect against various infectious diseases. Based on previous observations and recent exciting research, some strong evidence also shows that immune stimulation through vaccination, as well as microbial and non-microbial stimuli, can alter the immune system in such a way that it also increases immune protections against unrelated pathogens. These are the so-called “non-specific effects” (NSEs). Recently, NSEs involving the training of the innate defenses known as “trained immunity” have been the subject of many studies in humans and other species, including livestock. In the current Special Issue, all original studies and reviews presenting research in relation with NSE and particularly trained immunity in humans and domestic species are welcome. Please do not hesitate to submit.

Guest Editors

Dr. François Meurens

Swine and Poultry Infectious Diseases Research Center (CRIPA),
Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe,
QC J2S 2M2, Canada

Dr. Fanny Renois

BIOEPAR, INRAE, Oniris, 44307 Nantes, France

Prof. Dr. Jianzhong Zhu

College Veterinary Medicine, Yangzhou University, Yangzhou 225009,
China

Deadline for manuscript submissions

closed (18 February 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/89906

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).